🇺🇸 FDA
Pipeline program

APX005M treatment for recurrent or refractory primary malignant CNS tumor patients

PBTC-051

Phase 1 mab active

Quick answer

APX005M treatment for recurrent or refractory primary malignant CNS tumor patients for Glioblastoma Multiforme is a Phase 1 program (mab) at Pyxis Oncology with 1 ClinicalTrials.gov record(s).

Program details

Company
Pyxis Oncology
Indication
Glioblastoma Multiforme
Phase
Phase 1
Modality
mab
Status
active

Clinical trials